Questions regarding GynTect?

Get the answers!

Questions regarding GynTect?

Get the answers!

Welcome at oncgnostics GmbH Jena

As a biotechnology company, we at oncgnostics GmbH have been working on the diagnosis of cancer on a molecular biological basis since 2012. Our cancer tests are used in early cancer detection and diagnosis.

Our first product, GynTect®, was developed with the aim of improving the early detection of cervical cancer. The molecular biological test for cervical cancer has been on the market since 2015 and exemplifies the technology we specialise in as a biotech company: Highly informative biomarkers patented by oncgnostics GmbH form the core of the company. Experienced scientists work together on innovative cancer diagnostics of the future.

As a spin-off of the University Women’s Hospital Jena, oncgnostics GmbH with its research and development team works with international partners on various pipeline projects.

oncgnostics GmbH – Molecular Biotechnology from Jena

Jena provides us, oncgnostics GmbH, with the advantages of the university and high-tech city that allows us to work as a young research team on innovations in the field of molecular diagnostics. Experienced scientists can thus work together to lay the foundations for improved cancer diagnostics in the future.

Investors and partners

Partner oncgnostics GmbH

Molecular biological tests based on epigenetic biomarkers that enable early, reliable and rapid cancer diagnostics – that is the goal of oncgnostics GmbH. For studies, projects or international sales we collaborate with various partners.

About us

oncgnostics GmbH

The management of oncgnostics GmbH consists of the founding members of the company. A highly motivated and constantly growing team of industry-experienced employees and ambitious scientists work at oncgnostics GmbH.

Products

GynTect® supports the early detection of cervical cancer. In addition, oncgnostics GmbH develops molecular biological cancer tests for head and neck tumours and ovarian cancer and is working on further research projects.

GynTect® – the molecular biological test for cervical cancer

Detailed information on GynTect®, our molecular biological test for cervical cancer, is available at

In addition to a special section for laboratories and gynaecologists, patients can also find interesting information about cervical cancer and cervical cancer screening.

GynTect Test auf Gebärmutterhalskrebs
Your registration could not be saved. Please try again.
Your registration was successful.

Newsletter

If you would like us to keep you informed about news related to our company, please sign in for our quarterly newsletter.

You can unsubscribe from the newsletter at any time via the link in our newsletter.

Wir verwenden Sendinblue als unsere Marketing-Plattform. Wenn Sie das Formular ausfüllen und absenden, bestätigen Sie, dass die von Ihnen angegebenen Informationen an Sendinblue zur Bearbeitung gemäß den Nutzungsbedingungen übertragen werden.

News und Aktuelles

Molekularbiologische Krebs-Diagnostik - oncgnostics auf der MEDICA

Molecular biological cancer diagnostics close gaps in cancer screening

Two tests for cervical cancer with different objectives in cervical cancer screening Liquid biopsy for rapid and gentle diagnosis of head and neck tumours Current studies: GynTect DNA methylation test more sensitive than cytological…
2023 PM Oncgnostics Investment

Hong Kong firm invests in Jena-based Oncgnostics GmbH

Jena, September 05, 2023. The Hong Kong-based company Grande Bio-tech Co. Ltd. is making a seven-digit Euros investment in the Jena-based diagnostic company Oncgnostics GmbH. Oncgnostics has developed the cancer diagnostic Gyntect for the reliable…
Gedenken an Harald zur HausenArmin Kuebelbeck ;Net Vector / Shutterstock.com

Harald zur Hausen – in memory of a pioneer of cancer prevention

Prof. Dr Harald zur Hausen died on 28 May 2023. With his research, he laid the foundation for a new way of cancer prevention. We at oncgnostics commemorate the internationally renowned virologist not only because of his pioneering spirit, but…
Innovation trough research

Certain projects in our company are co-financed by the European Union with ERDF and ESF funds and the Free State of Thuringia (Thuringian Ministry of Economic Affairs, Science and Digital Society).